Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By PR Newswire
Last update: May 8, 2025
-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 --
-- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) --
Read more at prnewswire.comNASDAQ:QTTB (11/21/2025, 8:00:01 PM)
2
+0.07 (+3.63%)
Find more stocks in the Stock Screener
